-100%

est. 2Y upside i

HealthcareSeries B

Rank

#4465

Sector

Biotechnology, Women's Health

Est. Liquidity

~0Y

Data Quality

Data: Medium

This analysis reveals a critical issue: OvaScience is a defunct company, having undergone a reverse merger with Millendo Therapeutics in 2018, which subsequently merged with Tempest Therapeutics in 2021.

Last updated: March 10, 2026

Bull (5%)-100%

The job seeker quickly identifies that OvaScience is defunct and successfully clarifies the offer, potentially finding a legitimate opportunity elsewhere. However, any equity in the non-existent OvaScience is worthless, representing a -100% return from the stated $1.0B valuation.

Base (15%)-100%

The job seeker realizes OvaScience is no longer a standalone entity and its original equity is worthless. The offer for 'OvaScience' equity is meaningless, resulting in a -100% return from the stated $1.0B valuation.

Bear (80%)-100%

The job seeker accepts an offer based on the mistaken belief that OvaScience is a standalone, $1.0B company. The equity proves to be entirely worthless as the company is defunct, leading to a -100% return from the stated $1.0B valuation.

Est. time to liquidity~0.0 years

Preference Stack Risk

severe

Funding Intensity

28%

The original OvaScience raised $280M in funding. Given its defunct status, any original common stock would have been severely impacted by liquidation preferences during the mergers, likely resulting in $0 value.

Dilution Risk

high

Original OvaScience equity has been diluted to zero value through subsequent mergers. Any new equity would be subject to the dilution profile of the current entity (Tempest Therapeutics).

Secondary Liquidity

none

There is no secondary market for OvaScience equity as the company is defunct. Tempest Therapeutics (TPST) is publicly traded, but its shares are distinct from any original OvaScience holdings.

Questions to Ask at the Interview

Strategic questions based on OvaScience's data — designed to show you've done your homework.

  • 1

    “Could you please clarify the exact legal entity and ticker symbol of the company offering the equity, as my research indicates OvaScience is defunct and its assets are now part of Tempest Therapeutics (TPST)?”

  • 2

    “Given OvaScience's history of regulatory challenges and eventual merger, what is the current company's strategy for navigating regulatory pathways and ensuring product commercialization?”

  • 3

    “What is the current market capitalization and recent funding history of the company offering the equity, and how does the proposed equity package (RSUs/options) relate to the current valuation and any liquidation preferences?”

Community

Valuation Sentiment

Our model estimates -100% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.